86 related articles for article (PubMed ID: 21256247)
21. A composite design for transition from a preliminary to a full-scale study.
Lachin JM; Younes N
Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
[TBL] [Abstract][Full Text] [Related]
22. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
24. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
Kocherginsky M; Cohen EE; Karrison T
J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
[TBL] [Abstract][Full Text] [Related]
25. A two-stage phase II trial design utilizing both primary and secondary endpoints.
Lin X; Allred R; Andrews G
Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
[TBL] [Abstract][Full Text] [Related]
26. Estimation of multiple response rates in phase II clinical trials with missing observations.
Chang M
J Biopharm Stat; 2009 Sep; 19(5):791-802. PubMed ID: 20183444
[TBL] [Abstract][Full Text] [Related]
27. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
De Ridder F
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
[TBL] [Abstract][Full Text] [Related]
28. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Kelly PJ; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
[TBL] [Abstract][Full Text] [Related]
29. Phase II stopping rules that employ response rates and early progression.
Goffin JR; Tu D
J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
[TBL] [Abstract][Full Text] [Related]
30. A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial.
Guo HY; Liu A
J Biopharm Stat; 2005; 15(5):773-81. PubMed ID: 16078384
[TBL] [Abstract][Full Text] [Related]
31. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
32. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
33. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
34. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
35. Multinomial phase II cancer trials incorporating response and early progression.
Zee B; Melnychuk D; Dancey J; Eisenhauer E
J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698
[TBL] [Abstract][Full Text] [Related]
36. Early selection in a randomized phase II clinical trial.
Steinberg SM; Venzon DJ
Stat Med; 2002 Jun; 21(12):1711-26. PubMed ID: 12111907
[TBL] [Abstract][Full Text] [Related]
37. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
38. One- and two-stage designs for stratified phase II clinical trials.
London WB; Chang MN
Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
[TBL] [Abstract][Full Text] [Related]
39. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
40. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]